Your browser doesn't support javascript.
loading
A Phase II Study of Azacitidine, Venetoclax, and Trametinib in Relapsed or Refractory Acute Myeloid Leukemia Harboring RAS Pathway-Activating Mutations.
Desikan, Sai Prasad; Ravandi, Farhad; Pemmaraju, Naveen; Konopleva, Marina; Loghavi, Sanam; Jabbour, Elias J; Daver, Naval; Jain, Nitin; Chien, Kelly S; Maiti, Abhishek; Montalban-Bravo, Guillermo; Kadia, Tapan M; Macaron, Walid; DeLumpa, Ricardo; Kwari, Monica; Borthakur, Gautam; Short, Nicholas J.
Afiliação
  • Desikan SP; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Ravandi F; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Pemmaraju N; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Konopleva M; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Loghavi S; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Jabbour EJ; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Daver N; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Jain N; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Chien KS; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Maiti A; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Montalban-Bravo G; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Kadia TM; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Macaron W; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • DeLumpa R; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Kwari M; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Borthakur G; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Short NJ; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Acta Haematol ; 145(5): 529-536, 2022.
Article em En | MEDLINE | ID: mdl-35717939
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Azacitidina / Leucemia Mieloide Aguda Limite: Humans Idioma: En Revista: Acta Haematol Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Azacitidina / Leucemia Mieloide Aguda Limite: Humans Idioma: En Revista: Acta Haematol Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos